Current and future clinical utilities of Parkinson’s disease and dementia biomarkers: can they help us conquer the disease?-Reference-Cited by-同舟云学术

Current and future clinical utilities of Parkinson’s disease and dementia biomarkers: can they help us conquer the disease?

Published:2019-08-09 Issue:11 Volume:19 Page:1149-1161
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Ho Gilbert¹,Takamatsu Yoshiki²,Waragai Masaaki²,Wada Ryoko²,Sugama Shuei³,Takenouchi Takato⁴,Fujita Masayo²,Ali Alysha¹,Hsieh Mindy Hsin-I¹,Hashimoto Makoto²

Affiliation:

1. PCND Neuroscience Research Institute, Poway, CA, USA

2. Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

3. Department of Physiology, Nippon Medical School, Tokyo, Japan

4. Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, Tsukuba, Japan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Clinical Neurology,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2019.1649141

Reference123 articles.

1. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study

2. α-Synuclein in Lewy bodies

3. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

4. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

5. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2;Drug Discovery Today;2021-08

2. Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?;Frontiers in Endocrinology;2020-03-04